Business Wire

Travelxp 4K Joins SES Ultra HD Line-up in North America

Del

SES S.A. (Euronext Paris:SESG) (LuxX:SESG) today announced that Travelxp 4K, an international travel channel, will make its Ultra HD debut next month on SES’s growing Ultra HD distribution platform serving cable operators and multichannel television platforms throughout North America.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161218005060/en/

Offering audiences compelling stories from faraway places, the world’s first 4K travel channel, Travelxp 4K, is set to launch on the SES-1 satellite, one of a trio of SES satellites (SES-1, SES-3, AMC-18) that are home to the region’s leading Ultra HD distribution platform. Travelxp 4K, licensed to multichannel video program distributors (MVPDs) by Vivicast Media, is the latest in a series of Ultra HD channels to join SES’s Ultra HD platform, home to nine linear Ultra HD channels as of January. SES has now signed distribution agreements with more than 30 Ultra HD channels globally, of which 21 are commercial.

Travelxp 4K, a venture of Celebrities Management Private Limited in India, features hundreds of hours of world class travel programs filmed all over the world. The 4K channel follows the success of Travelxp HD, which offers 100% originally-produced premium travel and lifestyle programming distributed to over 50 million homes globally. Travelxp 4K will showcase global travel content with breathtaking images in 10 bit REC2020 color space with HLG (Hybrid Log Gamma) HDR (High Dynamic Range).

“Travelxp 4K is all about bringing the world to homes in stunning resolution. 10 bit REC2020 with HLG HDR will make the viewing experience more immersive and vivid. It’s not just about more pixels in 4K but better pixels,” explained Prashant Chothani, CEO, Travelxp 4K. “We are delighted to offer viewers a closer and more fascinating look at the world’s most beautiful travel destinations, cultures, and heritage like never before with our 100% original and exclusive 4K programming. By joining SES’s growing Ultra HD bouquet and content distribution platform, Travelxp 4K is well-positioned to reach significant audiences across North America.”

“SES has created the best and largest bouquet of stunning 4K programming in a single location around the world,” said Steve Corda, Vice President of Business Development in North America for SES. “People across the U.S. and North America are purchasing Ultra HD TVs at a record pace, with a surge expected this holiday season. Millions of television viewers are now expecting to watch 4K programming on their new screens, and cable operators and other television platform providers are on the verge of satisfying this growing demand with the historic home delivery of linear Ultra HD in the coming weeks and months.”

Follow us on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: https://www.ses.com/news/blogs
SES White papers are available under https://www.ses.com/news/whitepapers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at: www.ses.com.

About Celebrities Management Private Limited

Celebrities Management Private Limited is a privately held company in India, with interest in broadcast, advertising, media consulting and other related services. The company operates 7 (seven) satellite channels across the globe across its group companies.

Further information available at: www.travelxp.tv

About Vivicast Media

Vivicast Media is a leading source of the finest quality 4K programming and 24/7 linear networks. As a forward-thinking media company, Vivicast was one of the first companies to offer linear content geared toward the OTT market and has shown that same commitment to 4K/Ultra HD. Vivicast Media is a one-stop source of the very best 4K content the entertainment business has to offer.

Further information available at: www.vivicast.com

Contact information

For further information please contact:
SES S.A.
Markus Payer, +352 710 725 500
Corporate Communications
Markus.Payer@ses.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i